Medicenna Therapeutics Corp. (TSX:MDNA)

Medicenna Therapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is April - March.

Operating Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	-18.56	-18.41	-11.81	-25.47	-10.05	-22.58
Depreciation & Amortization	0.07	0.07	0.05	0	0	0.04
Stock-Based Compensation	1.53	1.59	2.21	1.21	1.37	1.42
Other Operating Activities	-4.72	-4.75	-8.27	7.25	-6.39	-0.62
Change in Accounts Receivable	0.97	2.56	-0.21	1.68	1.23	-0.39
Change in Accounts Payable	1.91	1.01	1.52	-0.94	1.18	-1.45
Operating Cash Flow	-18.81	-17.92	-16.49	-16.26	-12.66	-23.58
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-	-	-0.03	-	-	-
Sale of Property, Plant & Equipment	0	0	-	-	-	-
Investment in Securities	-	-	-	-	-	10.05
Investing Cash Flow	0	0	-0.03	-	-	10.05

Financing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Long-Term Debt Repaid	-	-0.07	-0.02	-	-	-0.04
Lease Payments	-0.08	-0.07	-0.02	-	-	-0.04
Total Debt Repaid	-0.08	-0.07	-0.02	-	-	-0.04
Net Debt Issued (Repaid)	-0.08	-0.07	-0.02	-	-	-0.04
Issuance of Common Stock	3.9	0.05	23.81	-	24.76	3.92
Other Financing Activities	-	-	-0.3	-	-	-
Financing Cash Flow	3.82	-0.02	23.49	-	24.76	3.88

Net Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	0.22	-0.65	0.89	-0.35	0.96	-0.18
Net Cash Flow	-14.77	-18.59	7.86	-16.61	13.06	-9.84

Free Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	-18.81	-17.92	-16.53	-16.26	-12.66	-23.58
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-0.22	-0.21	-0.22	-0.23	-0.20	-0.43
Levered Free Cash Flow	-10.79	-10.07	-10.24	-13.86	-4.41	-15.14
Unlevered Free Cash Flow	-10.79	-10.07	-10.24	-13.86	-4.41	-15.14
Free Cash Flow After Leases	-18.89	-17.99	-16.54	-16.26	-12.66	-23.62

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Change in Working Capital	2.88	3.58	1.31	0.74	2.41	-1.84

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 3, 2026

Data Sources Report a data error